<?xml version="1.0" encoding="UTF-8"?>
<response>

<lst name="responseHeader">
  <int name="status">0</int>
  <int name="QTime">16</int>
  <lst name="params">
    <str name="echoParams">explicit</str>
    <str name="indent">true</str>
    <str name="file">data-lines/./reut2-010.sgm-553.txt</str>
    <str name="usePOS">false</str>
    <str name="sentences">3</str>
    <str name="wt">xml</str>
    <str name="formula">tfidf</str>
  </lst>
</lst>
<lst name="analysis">
  <lst name="summary">
    <lst name="stats">
      <lst name="sentences">
        <int name="count">20</int>
      </lst>
      <lst name="terms">
        <int name="count">94</int>
      </lst>
      <lst name="stems">
        <int name="count">60</int>
      </lst>
    </lst>
    <lst name="terms">
      <lst name="term">
        <str name="text">cents</str>
        <double name="strength">1.0</double>
      </lst>
      <lst name="term">
        <str name="text">revenues</str>
        <double name="strength">0.9999999999999989</double>
      </lst>
      <lst name="term">
        <str name="text">effects</str>
        <double name="strength">0.9999999999999984</double>
      </lst>
      <lst name="term">
        <str name="text">share</str>
        <double name="strength">0.5590169943749472</double>
      </lst>
      <lst name="term">
        <str name="text">action</str>
        <double name="strength">0.5</double>
      </lst>
    </lst>
    <lst name="sentences">
      <lst name="sentence">
        <str name="text">Stuart Weisbrod, a biotechnology analyst with Prudential Bache Securities Inc., told Reuters the additional FDA review likely would keep TPA off the market until at least November.</str>
        <int name="index">15</int>
        <int name="start">1</int>
        <int name="end">181</int>
        <double name="strength">1.0</double>
      </lst>
      <lst name="sentence">
        <str name="text">He said the FDA action prompted him to cut his estimate of Genentech's 1987 earnings to about 40 cents a share from his earlier projection of 67 cents a share.</str>
        <int name="index">17</int>
        <int name="start">1</int>
        <int name="end">160</int>
        <double name="strength">0.9773358766263931</double>
      </lst>
      <lst name="sentence">
        <str name="text">TPA stands for tissue plasminogen activator, and would be used on heart attack victims to clear blockage in a vein or artery.</str>
        <int name="index">12</int>
        <int name="start">1</int>
        <int name="end">126</int>
        <double name="strength">0.9598520557347798</double>
      </lst>
    </lst>
    <lst name="highlighted">
      <lst name="sentence">
        <str name="text">&lt;em&gt;Stuart Weisbrod,&lt;/em&gt; a &lt;em&gt;biotechnology analyst&lt;/em&gt; with &lt;em&gt;Prudential Bache Securities&lt;/em&gt; Inc., told &lt;em&gt;Reuters&lt;/em&gt; the &lt;em&gt;additional&lt;/em&gt; FDA &lt;em&gt;review likely would&lt;/em&gt; keep TPA off the &lt;em&gt;market until&lt;/em&gt; at &lt;em&gt;least November&lt;/em&gt;.</str>
        <int name="index">15</int>
      </lst>
      <lst name="sentence">
        <str name="text">He said the FDA &lt;em&gt;action prompted&lt;/em&gt; him to cut his &lt;em&gt;estimate&lt;/em&gt; of &lt;em&gt;Genentech&lt;/em&gt;'s 1987 &lt;em&gt;earnings&lt;/em&gt; to &lt;em&gt;about 40 cents&lt;/em&gt; a &lt;em&gt;share&lt;/em&gt; from his &lt;em&gt;earlier projection&lt;/em&gt; of 67 &lt;em&gt;cents&lt;/em&gt; a &lt;em&gt;share&lt;/em&gt;.</str>
        <int name="index">17</int>
      </lst>
      <lst name="sentence">
        <str name="text">TPA &lt;em&gt;stands&lt;/em&gt; for &lt;em&gt;tissue plasminogen activator,&lt;/em&gt; and &lt;em&gt;would&lt;/em&gt; be used on &lt;em&gt;heart attack victims&lt;/em&gt; to &lt;em&gt;clear blockage&lt;/em&gt; in a vein or &lt;em&gt;artery&lt;/em&gt;.</str>
        <int name="index">12</int>
      </lst>
    </lst>
  </lst>
</lst>
</response>
